Communiqués IO Biotech, Inc.

Actions

IOBTQ

US4497781090

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 21:25:20 04/06/2026			Varia. 5j.	Varia. 1 janv.
0,007000 ^USD	+218,18%		+250,00%	-98,85%

19/08	Le vaccin de Moderna et Merck contre le mélanome en tête de la course au premier vaccin thérapeutique contre le cancer	RE
31/03	IO Biotech, Inc. se déclare en faillite	CI

Communiqués

02/02	IO Biotech Provides Corporate Update	AQ
30/01	IO Biotech Provides Corporate Update	AQ
21/01	IO Biotech Announces Exploration of Strategic Alternatives	AQ
15/12	IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications	AQ
26/11	IO Biotech Announces Participation in Upcoming December Investor Conferences	AQ
14/11	IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights	AQ
12/11	IO Biotech Announces Participation in Upcoming Investor Conferences	AQ
07/11	IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)	AQ
21/10/25	IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA in First-line Advanced Melanoma at ESMO 2025	AQ
20/10/25	IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025	AQ
23/09/25	IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025	AQ
04/09/25	IO Biotech Announces Participation in Upcoming Investor Conferences	AQ
14/08/25	IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights	AQ
12/08/25	IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio(R) in Combination with KEYTRUDA(R) (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma	AQ
12/08/25	IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio plus KEYTRUDA for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed	AQ
11/08/25	IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed	AQ
10/08/25	IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma	AQ
20/05/25	IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference	AQ
14/05/25	IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights	AQ
26/04/25	IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025	AQ
25/04/25	IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170	AQ
28/03/25	Denmark: IO Biotech secures up to EUR57.5 million EIB venture debt to advance cancer vaccine research and development	AQ
25/03/25	IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting	AQ
18/03/25	IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025	AQ
04/03/25	IO Biotech Reports 2024 Business Highlights	AQ